New hope for skin cancer patients suffering from severe gut side effects of immunotherapy
NCT ID NCT04305145
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This study tests if the drug infliximab can treat severe colitis (gut inflammation) caused by immunotherapy in people with advanced skin cancer. About 42 participants will receive either infliximab or steroids to see which works better at stopping symptoms without needing long-term steroids. The goal is to find a safer, more effective way to manage this common side effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.